Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

Here’s why Proteomics (ASX:PIQ) shareholders should brace themselves for a big 2025!

Proteomics (ASX:PIQ) is one of the healthcare stocks to watch in CY25, because it has not one, not two, but three diagnostic tests to be commercialised in Australia, the USA and Europe. It has been a long wait to get to this point, but investors can be confident that there is upside to be realised if…

ByNick SundichDecember 12, 2024

Island Pharmaceuticals’ PROTECT clinical trial is delivering the goods!

Investors were evidently pleased with the results out of Island Pharmaceuticals' PROTECT clinical trial...at least if the company's more than doubling in the past two months is anything to go by. The results don't just offer hope to Island's investors, but to people suffering from and vulnerable to Dengue fever, a virus that impacts 400m…

ByNick SundichDecember 5, 2024

Here are 6 ASX CEOs who departed their companies in 2024

Here are 6 ASX CEOs who departed their companies in 2024 Larry Diamond - Zip (ASX:ZIP) Since Afterpay's acquisition, Zip (ASX:ZIP) has been the flagship BNPL company of the ASX. It managed to survive a cash crunch, a spectacular collapse in its valuation as interest rates rose, a merger attempt with Sezzle that ended…

ByNick SundichDecember 5, 2024

These 2 key milestones awaiting Recce Pharmaceuticals could be very exciting and value accretive!

There are 2 key milestones awaiting Recce Pharmaceuticals (ASX:RCE) in the next few months that investors in this company need to look out for.The company has had substantial news flow including clinical trial progress, R&D tax rebates and partnerships for its future clinical endeavours, but only a few have generated significant excitement. Arguably, the most…

ByNick SundichNovember 25, 2024

The $8.8bn Chemist Warehouse Sigma merger is finally going ahead with the ACCC not killing it off

Nearly a year since the $8.8bn Chemist Warehouse Sigma merger was unveiled, it seems we finally got a definitive answer as to whether or not it will go ahead. The ACCC investigated the deal and there was the risk of it blocking the deal if it reckons it will lessen competition. After all, it raised…

ByNick SundichNovember 11, 2024

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

There are encouraging signs from Recce Pharmaceuticals' (ASX:RCE) Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections). The trial, is nearing completion, but the results to date have led to a Non-Data Safety Monitoring Board reviewing the trial unanimously recommending it continue.Not only have there been no serious adverse events, but all…

ByNick SundichNovember 6, 2024

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Imugene (ASX:IMU) is still valued at over $400m, in spite of being valued at over $2bn back in 2021 and having had a rollercoaster 12 months. Imugene (ASX:IMU) share price chart, log scale (Source: TradingView) Even though it has assets that have passed Phase 2 trials, it has never gotten to Phase 3. Yet it has $93.1m…

ByNick SundichOctober 22, 2024

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons why.For many companies, the golden market has been the USA, given its population and stringent regulator the Food and Drug Administration (FDA). If a company can commercialise a drug in the USA, it can succeed…

ByNick SundichOctober 15, 2024

Want to participate in the ASX Schools Sharemarket Game? Here are Some Top Strategies for Success!

The ASX Schools Sharemarket Game is on again! And it is a great way for school students to be introduced to the strategic functioning of the share markets. But just because you're not using actual money, it doesn't mean you should take it seriously. This blog will identify the best practices to assist you in…

ByUjjwal MaheshwariOctober 1, 2024

Here Are The Top 5 Websites for Stock Market News & Analysis in Australia

For Australian investors and traders, staying informed about stock market news is essential for making smart decisions. With a range of websites now providing real-time data, expert analysis, and market insights, investors have the tools to navigate the ever-changing world of stocks. This article highlights five of the most reliable websites offering stock market news…

ByUjjwal MaheshwariSeptember 25, 2024

the Kick-ass Multipurpose WordPress Theme

Life Sciences

Here’s why Proteomics (ASX:PIQ) shareholders should brace themselves for a big 2025!

Island Pharmaceuticals’ PROTECT clinical trial is delivering the goods!

Here are 6 ASX CEOs who departed their companies in 2024

These 2 key milestones awaiting Recce Pharmaceuticals could be very exciting and value accretive!

The $8.8bn Chemist Warehouse Sigma merger is finally going ahead with the ACCC not killing it off

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Here Are The Top 5 Websites for Stock Market News & Analysis in Australia

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Life Sciences

Stocks in Spotlight

Add Your Heading Text Here